Key result
Major bleeding occurred in 1.4% of VTE patients treated with edoxaban and 1.6% with warfarin; a model using five clinical factors predicted bleeding on edoxaban with a C-statistic of 0.71.
Why the study?
What are the risk factors for major and clinically relevant bleeding in patients receiving edoxaban or warfarin for acute VTE?
Cohort (n=8,240)
What are the risk factors for major and clinically relevant bleeding in patients receiving edoxaban or warfarin for acute VTE?
Absolute Event Rate: 1.4% vs 1.6%
Five main predictors (female sex, concomitant antiplatelet therapy, haemoglobin ≤10 g/dl, history of arterial hypertension, and systolic blood pressure >160 mmHg) can identify patients at increased risk of major bleeding when treated with edoxaban for acute VTE.
No takes yet. Share an insight, caveat, or question.
May inform individualized bleeding risk assessment during VTE anticoagulation; leaves open prospective validation before guiding treatment decisions.
Raskob et al. (2017) conducted a cohort in acute venous thromboembolism (VTE) (n=8,240). Edoxaban vs. Warfarin was evaluated on Major bleeding. Major bleeding occurred in 1.4% of VTE patients treated with edoxaban and 1.6% with warfarin; a model using five clinical factors predicted bleeding on edoxaban with a C-statistic of 0.71.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: